11 October 2022: Original Paper
Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies
Shu Fang 12ABCDEF* , Nan Wang 23ABCF* , Lili Wang 2ABCD* , Jishan Du 23BCF , Jingjing Yang 23BCF , Yanan Wen 23BCF , Yan Wei 23BCF , Kun Qian 12BCD , Hao Wang 23ABF , Yifan Jiao 23BCF , Chunji Gao 12ACEG* , Liping Dou 2ABDEG*DOI: 10.12659/AOT.937356
Ann Transplant 2022; 27:e937356
Table 4 Multivariate analysis of risk factors for transplant outcomes in all patients.
| Variables | HR | 95% CI | p |
|---|---|---|---|
| Grades 2–4 aGVHD | |||
| Donor-recipient ABO match | |||
| Mismatch vs match | 1.978 | 0.933–4.192 | 0.075 |
| Time interval between diagnosis and HSCT | |||
| ≥6 m vs | 2.032 | 0.943–4.380 | 0.070 |
| CD34 (≥ median vs < median) | 1.976 | 0.911–4.289 | 0.085 |
| Chronic GVHD | |||
| Diagnosis (ALL vs others) | 0.791 | 0.288–2.173 | 0.650 |
| ATG vs non-ATG | 0.251 | 0.108–0.582 | 0.001 |
| Disease risk index | |||
| High/very high vs low/intermediate | 0.414 | 0.158–1.083 | 0.072 |
| Moderate to severe cGVHD | |||
| ATG vs non-ATG | 0.314 | 0.103–0.958 | 0.042 |
| Recipient age (≥ median vs < median) | 0.428 | 0.161–1.143 | 0.090 |
| Extensive cGVHD | |||
| ATG vs non-ATG | 0.269 | 0.073–0.995 | 0.049 |
| CIR | |||
| Diagnosis (ALL vs others) | 1.536 | 0.728–3.241 | 0.260 |
| ATG vs non-ATG | 2.337 | 1.133–4.822 | 0.022 |
| Time interval between diagnosis and HSCT | |||
| ≥6 m vs < 6 m | 0.520 | 0.253–1.071 | 0.076 |
| GRFS | |||
| Disease risk index | |||
| High/very high vs low/intermediate | 1.654 | 0.979–2.792 | 0.060 |
| CD34 (≥ median vs < median) | 1.785 | 1.067–2.984 | 0.027 |
| OS | |||
| Time interval between diagnosis and HSCT | |||
| ≥6 m vs | 0.559 | 0.266–1.176 | 0.125 |
| DFS | |||
| Time interval between diagnosis and HSCT | |||
| ≥6 m vs | 0.593 | 0.311–1.133 | 0.114 |
| ATG – anti-thymocyte globulin; aGVHD – acute graft-versus-host disease; cGVHD – chronic graft-versus-host disease; HSCT – hematopoietic stem cell transplantation; ALL – acute lymphoblastic leukemia; CR – complete remission; MNCs – mononuclear cells. | |||